Recently, Daiichi Sankyo Pharmaceutical (Shanghai) Co., Ltd. and Pfizer Investment Co., Ltd. announced that they have reached an agreement, from 2011, joint marketing in mainland China the first three of the original research of angiotensin Ⅱ receptor antagonist ( ARB) class of anti-hypertensive drugs - Ao Tan. The partnership is the second in 2009 and Takeda co-promote the extension after Viagra, Pfizer's second collaboration with Japanese companies to promote drugs.

Cooperation period is December 1, 2010 to December 31, 2020, a total of 10 years. The two companies will adopt a unified market strategy, carried out jointly in the country. Promotion will be included in areas where health care center, full-time each of the parties established a joint promotion of the cardiovascular team.

This reporter has learned that the joint promotion will be based on anti-hypertensive drugs in the drug field advantage, and make full use of the first three anti-hypertension drug, and Pfizer in the field of brand influence, extensive coverage of business and professional medical services, the potential ability to enhance brand awareness, market competitiveness, and promote the academic level.

Urgent need to enhance the performance

Although proud of tanks in 2006 had entered the Chinese market, but the drug failed to catch up with the 2009 health insurance directory to adjust, and therefore its sales performance has been poor.

According to statistics, over the years, the annual Tan proud of only about 100,000 boxes sold, while sales in 2009, only 2.915 million yuan, although access to local health insurance through the directory, its performance has improved, but only 4.423 million yuan .

The performance is not satisfactory with the opposite in China, proud of hypertension in the U.S. market tanks, but has achieved impressive results. Since 2002 in the United States has 25 million patients worldwide have taken the drug. The drug received a highly global pharmaceutical industry in the global market achieved excellent sales performance, has increased rapidly in the U.S. market ranked No. 2 of the ARB class of antihypertensive drugs.

However, the first three were insufficient in China to promote its products failed to achieve its proper performance, which is the prevalent phenomenon in Japanese pharmaceutical companies, therefore, better adapted to the Chinese market with the cooperation of Pfizer is a wise of choice.
The promotion of cooperation is the way Wu Xiaobin, General Manager of Pfizer China after taking office as an important strategic move in the cardiovascular field is Pfizer favorite market, "Pfizer's hypertension drug market in China is always the focus areas of long-term one. "According to Wu Xiaobin, the" in the cardiovascular field, Daiichi Sankyo has a strong R & D capabilities, we are very pleased to join forces with Daiichi Sankyo ARB to promote industry-leading products, Pfizer will make full use of excellent professional in China medical service capabilities and extensive distribution network of business coverage and benefits to achieve their sales increase. "
    Into the national health insurance
    According to IMS statistics, as many as 200 million Chinese people with hypertension, high blood pressure in 2009 the market size of 8.102 billion yuan, an increase of 35.3%. ARB market sales of 31.4 billion yuan, a growth rate of 38.8%.

However, the market is extremely competitive, therefore, the first three Republican Pfizer is very optimistic about the partnership, according to the first three terms were introduced: "Our bilateral cooperation is expected to be in 10 years convinces the drug's total sales to 7.8 billion yuan, the first 10 years of single-year sales exceeded 20 billion yuan, and become among the top three of the ARB drugs.

According to the reporter, Tan now has pride in Shanghai, Guangxi, Hubei, Henan and other provinces of the 11 "basic medical insurance, industrial injury insurance and maternity insurance drug list", and therefore its market prospects has also been recognized by Pfizer."The first three were hoping to use this opportunity to further expand in China's pharmaceutical business and improve the cardiovascular field in China's brand." The first three of the young general manager package just said, "In the future, Daiichi Sankyo will strengthen the academic and market mechanisms to promote our high quality products in the patients and medical workers in the availability, through this partnership will further enhance the promotion of academic level, so proud of tanks for the next round of adjustments to the national health insurance health insurance directory. " (from Medicine Economic News)